Vibha Ravi
Senior Editor
Vibha provides news and analysis for Pink Sheet and Scrip on a broad range of subjects related to companies, including deals, strategy, regulation and policy. Her multimedia content including infographics and podcasts have helped her win internal awards. She brings her education in business management and experience as a senior journalist for AFX-Asia to bear in spotting trends. As an attendee and panelist at conferences, she strives to bring unique insights to the audience. In her spare time, she enjoys travel, photography and blogging.
Latest From Vibha Ravi
Deal Watch: A Closer Look At Boehringer Ingelheim’s Partnering Strategy
Plus deals involving AbbVie/Ripple, Novo Nordisk/Korro Bio, Novo Nordisk/NanoVation, Bharat, Alopexx, Gilead/Genesis, Lilly/Genetic Leap, Contraline/Population Council, Proveca/Cessatech, Vivtex/Equillium and more.
Former Hilleman CEO On Microbiome Project, Cholera, Halal Vaccine
Human milk could have a role in preventing Alzheimer’s disease and other ailments linked to the gut microbiome, says former Pfizer VP and Hilleman CEO Davinder Gill. He also talks about a halal meningitis vaccine, and tailwinds for an oral cholera vaccine now launched by Bharat Biotech in this fascinating interview
Fast And Furious – Leqvio Licensed, Bharat Serums In Bag, Mankind Sets Eyes On 5X Growth
A licensing deal for Leqvio (inclisiran) is all in a day’s work for Mankind which also recently acquired Bharat Serums and Vaccines at a valuation investors were initially not entirely pleased with. As the youngest company in the top five of the domestic pharma market sets a 5X revenue target, what could help it get there and what’s to watch out for?
Zydus Buys Stake In Sterling Biotech – Will API Segment Restructuring Accelerate?
Does Zydus’ 50% stake acquisition in Sterling Biotech reflect a broader move of formulations companies to secure API supplies or acceleration of API segment restructuring begun by a couple of private equity (PE) funds?
Zydus Buys Stake In Sterling Biotech – Will API Segment Restructuring Accelerate?
Does Zydus’ 50% stake acquisition in Sterling Biotech reflect a broader move of formulations companies to secure API supplies or acceleration of API segment restructuring begun by a couple of private equity (PE) funds?
With Mpox Vaccine In Serum Institute Pipeline, What Could Favor India Vaccine Makers?
Serum Institute is working on an mpox vaccine while other Indian firms are weighing options after the WHO sounded an alert and a new case was reported in neighboring Pakistan. Scrip looks at factors that could favor development and/or manufacture of an mpox vaccine at Indian majors.